Many of the mechanisms responsible for cardiovascular disease and hypertension are well known, and gender is an independent risk factor in many cohorts. How gender contributes to cardiovascular disease has not been completely elucidated. Even in normotensive populations, blood pressure is higher in men than women, although why this occurs is unclear. While both men and women suffer from high incidences of cardiovascular disease, women are typically protected against cardiovascular disease until after menopause, so that on average they are about 10 years older than men when these diseases develop, making aging a confounding problem contributing to increased morbidity. Because hypertension is one of the leading causes of cardiovascular disease in both men and women, this review will focus on hypertension, and the mechanisms that have been found to play a role in mediating blood pressure control and how they differ in men and women.
It's obvious why only men develop prostate cancer and why only women get ovarian cancer. But it is not obvious why women are more likely to recover language ability after a stroke than men or why women are more apt to develop autoimmune diseases such as lupus. Sex differences in health throughout the lifespan have been documented. Exploring the Biological Contributions to Human Health begins to snap the pieces of the puzzle into place so that this knowledge can be used to improve health for both sexes. From behavior and cognition to metabolism and response to chemicals and infectious organisms, this book explores the health impact of sex (being male or female, according to reproductive organs and chromosomes) and gender (one's sense of self as male or female in society). Exploring the Biological Contributions to Human Health discusses basic biochemical differences in the cells of males and females and health variability between the sexes from conception throughout life. The book identifies key research needs and opportunities and addresses barriers to research. Exploring the Biological Contributions to Human Health will be important to health policy makers, basic, applied, and clinical researchers, educators, providers, and journalists-while being very accessible to interested lay readers.
On the occasion of the symposium on Hypertension in Postmenopausal Women (Monte Carlo, January 19-22, 1994), international scientists and clinicians discussed the various aspects of high blood pressure in older women. This volume presents an overview of this important aspect of both cardiology and gynecology. Special emphasis is given to the different approaches to antihypertension treatment.
Sex Differences in Physiology is an all-encompassing reference that details basic science research into sex differences in all physiological fields. It includes scientific discoveries concerning sex differences in cardiovascular, respiratory, renal, gastrointestinal, and musculoskeletal physiology. In addition, coverage of the development, endocrinology, neurophysiology, immunity, and metabolism is included, making this important reference a resource that will meet the needs of investigators interested in incorporating sex differences into their research programs, while also providing clinicians with the basis for providing the best sex-based medical treatment options available. Provides a sweeping, organ-by-organ review of currently observed sex differences in animal models and human disease Explains how sex differences influence physiology and disease Provides the critical knowledge on sex differences for better understanding of prevention and treatment of diseases
Cardiac Drugs describes the latest advances in the rapidly evolving area of cardiovascular pharmacology. Written by renowned, USbased experts in cardiology, this book discusses the drug groups for different diseases, such as acute coronary syndromes, hypertension, angina and heart failure. Separate chapters examine cardiac drugs in pregnancy and lactation, and future directions. Enhanced by full colour images and illustrations, this easy to follow text offers practical advice on how to manage cardiac diseases, with a focus on hands-on therapeutic guidance for clinicians.
This book is a concise, easy to read professional text with a focus on practical aspects. All chapters include tables on sex/gender differences in symptoms and management and a series of suggestions to the novice in the field. Chapters are specialty-specific. The focus is not on women’s health, but the presentation of differences in clinical symptoms, management and outcomes in women and men. Gender Medicine strives to employ the knowledge about these differences to improve diagnosis, better understand pathogenesis and advance patient-oriented therapy.
Cardiovascular disease is the leading cause of death in women in the US, with more women dying from heart disease than men. Women may have different presentation from men and often need a different approach to diagnosis and treatment. There are also unique topics of management of heart disease in women, including issues during pregnancy, lactation, and menopause. Many different health care providers, as well as cardiologists are involved in treating these patients. A manual reviewing diagnosis and treatment of cardiac disease in women would help providers without specific cardiology training to deliver care with greater efficiency. A practical and comprehensive guide geared towards these providers would be a highly practical and valuable resource that would be utilized in everyday practice in offices that include urban clinics, general medicine offices, obstetrics and gynecology offices, as well as in the surgical subspecialties. This book will be a highly practical resource that can be directly applied to the issues that arise in everyday practice. There is no available book on the market that focuses on a broader approach to cardiac disease in women or focuses on non-cardiology providers (and their trainees) who have the need to know more about treatment of cardiovascular disease in women.
This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed.
Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data-including population surveys, cohort studies, disease registries, administrative health data, and vital statistics-contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.
A trailblazing assessment of sex and gender differences in reactions to drug therapy, this volume reflects the topic’s growing recognition. Analyses by international experts on both pharmacokinetics and drug development are informed by an extensive data set.
